Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average rating of “Moderate Buy” from the twenty-four ratings firms that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $161.83.

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a research note on Thursday, April 3rd. Morgan Stanley lowered their price objective on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company started coverage on shares of Sarepta Therapeutics in a research report on Friday, April 11th. They issued an “overweight” rating and a $115.00 target price for the company. Finally, Royal Bank of Canada lowered shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 7.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SRPT. Louisiana State Employees Retirement System increased its holdings in Sarepta Therapeutics by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after purchasing an additional 100 shares in the last quarter. EP Wealth Advisors LLC increased its stake in shares of Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after buying an additional 105 shares during the period. Manchester Capital Management LLC raised its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. UMB Bank n.a. raised its holdings in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 138 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its position in Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after buying an additional 139 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $54.42 on Friday. The company’s 50-day moving average is $85.66 and its 200-day moving average is $109.22. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market capitalization of $5.28 billion, a PE ratio of 43.54 and a beta of 0.93. Sarepta Therapeutics has a fifty-two week low of $48.01 and a fifty-two week high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.